- Home
- SBET vs QNRX Comparison
SBET vs QNRX Comparison
Compare SBET & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBET | QNRX |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 10.1M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SBET | QNRX |
|---|---|---|
| Price | $10.07 | $14.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | ★ 8.6M | 49.8K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,106,030.00 | N/A |
| Revenue This Year | $78,838.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 239.01 | N/A |
| 52 Week Low | $2.26 | $5.01 |
| 52 Week High | $124.12 | $41.80 |
Technical Indicators
Market Signals| Indicator | SBET | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 49.18 |
| Support Level | $8.69 | $13.42 |
| Resistance Level | $10.72 | $14.25 |
| Average True Range (ATR) | 0.48 | 0.95 |
| MACD | 0.19 | 0.06 |
| Stochastic Oscillator | 67.57 | 57.73 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.